Results 231 to 240 of about 70,685 (301)

Prevalence and Risk Factors for Vaginal Flatus From Mid‐Pregnancy to 12 Months Postpartum: A Longitudinal Cohort Study

open access: yesBJOG: An International Journal of Obstetrics &Gynaecology, Volume 133, Issue 3, Page 487-494, February 2026.
ABSTRACT Objective To assess the prevalence of and trend in bothersome vaginal flatus from mid‐pregnancy to 12 months postpartum, according to vaginal parity. The secondary objective was to assess differences in pelvic floor anatomy as risk factors for bothersome flatus at 12 months postpartum. Design Longitudinal cohort study.
Marthe Dalevoll Macedo   +5 more
wiley   +1 more source

Lymphoepithelioma-like carcinoma of the distal urethra: a case report and management strategies. [PDF]

open access: yesJ Surg Case Rep
Fonseca R   +6 more
europepmc   +1 more source

A Scalable Organoid Model of Urothelial Aging for Metabolic Interrogation, Infection Modeling, and Reversal of Age‐Associated Changes

open access: yesAging Cell, Volume 25, Issue 2, February 2026.
mBEDOs: a scalable platform for modeling urothelial aging. mBEDOs derived from aged mouse bladders capture essential molecular and cellular features of urothelial aging and provide a versatile system for high‐throughput metabolic profiling, therapeutic screening via metabolite supplementation, age‐ and sex‐based analyses, infection modeling, and immune–
Adwaita R. Parab   +8 more
wiley   +1 more source

Vaginal "tunnel flap" technique for urethral neomeatus reconstruction after distal urethrectomy in advanced vulvar cancer: a case report with anatomical insights. [PDF]

open access: yesFront Med (Lausanne)
Ceccaroni M   +8 more
europepmc   +1 more source

Long‐term outcomes of a cascading salvage strategy for high‐risk non‐muscle‐invasive bladder cancer

open access: yesBJU International, Volume 137, Issue 2, Page 339-347, February 2026.
Objective To report long‐term oncological outcomes of patients with high‐risk non‐muscle‐invasive bladder cancer (HR‐NMIBC) undergoing bladder‐sparing therapy (BST) after bacillus Calmette–Guérin (BCG) failure. Patients and Methods We retrospectively reviewed patients with HR‐NMIBC treated from 2000 to 2025 with intravesical therapies after BCG failure,
Ian M. McElree   +5 more
wiley   +1 more source

Male urethra

open access: yes, 2013
Ian Bickle, Craig Hacking, Arlene Campos
openaire   +1 more source

Intravesical oxybutynin for bladder capacity in children with spina bifida: the ‘Place de l’OXybutynine Intravésicale chez le Patient Enfant Neurologique’ (POXIPEN) trial protocol

open access: yesBJU International, Volume 137, Issue 2, Page 390-398, February 2026.
Background Neurogenic bladder is defined as a dysfunction of the bladder resulting from damage to the central or peripheral nervous systems. Its treatment is based on a progressive therapeutic escalation, rapidly involving invasive therapeutic procedures such as repeated intradetrusor injections and surgery.
Marie Buzzi   +6 more
wiley   +1 more source

Home - About - Disclaimer - Privacy